Arsenic trioxide prevents nitric oxide production in lipopolysaccharide ‐stimulated RAW 264.7 by inhibiting a TRIF‐dependent pathway

Arsenic trioxide (ATO) is one of the most potent drugs in cancer chemotherapy, and is highly effective in treating both newly diagnosed and relapse patients with acute promyelocytic leukemia (APL). Despite a number of reports regarding the molecular mechanisms by which ATO promotes anti‐tumor or pro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Takahashi, Miyuki, Ota, Akinobu, Karnan, Sivasundaram, Hossain, Ekhtear, Konishi, Yuko, Damdindorj, Lkhagvasuren, Konishi, Hiroyuki, Yokochi, Takashi, Nitta, Masakazu, Hosokawa, Yoshitaka
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2012
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657247/
https://ncbi.nlm.nih.gov/pubmed/23106696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12053
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars